Vivek Subbiah wholeheartedly supports and endorses Dr. Giuseppe Curigliano for ESMO President 2027-28

Vivek Subbiah shared on X:

“Exciting news! The elections for the ESMO President 2027-2028 are happening from May 28 to June 10, 2024, when everyone here in USA is excited about ASCO24. .

I wholeheartedly support and endorse Dr. Giuseppe Curigliano, a visionary in oncology and an outstanding colleague for ESMO President 2027-28.

Giuseppe Curigliano’s groundbreaking research has made him one of the most influential researchers in 2022 and 2023. Let’s support him and cast our votes for a visionary in cancer research and editor-in-chief of ESMO Open.”

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).

He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.